These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 29913011)

  • 1. Anti-Myelin Oligodendrocyte Glycoprotein Antibody-Associated Central Nervous System Demyelination-A Novel Disease Entity?
    Weber MS; Derfuss T; Brück W
    JAMA Neurol; 2018 Aug; 75(8):909-910. PubMed ID: 29913011
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical and MRI phenotype of children with MOG antibodies.
    Fernandez-Carbonell C; Vargas-Lowy D; Musallam A; Healy B; McLaughlin K; Wucherpfennig KW; Chitnis T
    Mult Scler; 2016 Feb; 22(2):174-84. PubMed ID: 26041801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-myelin oligodendrocyte glycoprotein antibodies: Magnetic resonance imaging findings in a case series and a literature review.
    Cellina M; Fetoni V; Ciocca M; Pirovano M; Oliva G
    Neuroradiol J; 2018 Feb; 31(1):69-82. PubMed ID: 28379073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myelin Oligodendrocyte Glycoprotein-Associated Pediatric Central Nervous System Demyelination: Clinical Course, Neuroimaging Findings, and Response to Therapy.
    Thulasirajah S; Pohl D; Davila-Acosta J; Venkateswaran S
    Neuropediatrics; 2016 Aug; 47(4):245-52. PubMed ID: 27128728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical features and long-term outcome of a group of Japanese children with inflammatory central nervous system disorders and seropositivity to myelin-oligodendrocyte glycoprotein antibodies.
    Hino-Fukuyo N; Haginoya K; Nakashima I; Sato DK; Takahashi T; Misu T; Fujihara K; Hirose M; Kakisaka Y; Uematsu M; Kobayashi T; Kure S
    Brain Dev; 2015 Oct; 37(9):849-52. PubMed ID: 25748628
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of Autoantibodies Against Myelin Oligodendrocyte Glycoprotein in Multiple Sclerosis and Related Diseases.
    Spadaro M; Meinl E
    Methods Mol Biol; 2016; 1304():99-104. PubMed ID: 25814289
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The two faces of neuromyelitis optica.
    Weinshenker BG; Wingerchuk DM
    Neurology; 2014 Feb; 82(6):466-7. PubMed ID: 24415570
    [No Abstract]   [Full Text] [Related]  

  • 8. Atypical Pediatric Demyelinating Diseases of the Central Nervous System.
    Troxell RM; Christy A
    Curr Neurol Neurosci Rep; 2019 Nov; 19(12):95. PubMed ID: 31773416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disorders: Toward a New Spectrum of Inflammatory Demyelinating CNS Disorders?
    Di Pauli F; Berger T
    Front Immunol; 2018; 9():2753. PubMed ID: 30555462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Features of neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies.
    Gao J; Pan W; Zhang H
    JAMA Neurol; 2014 Jul; 71(7):923-4. PubMed ID: 25023552
    [No Abstract]   [Full Text] [Related]  

  • 11. Features of neuromyelitis optica spectrum disorders and aquaporin-4 with myelin-oligodendrocyte glycoprotein antibodies-reply.
    Kitley J; Waters P; Vincent A; Palace J
    JAMA Neurol; 2014 Jul; 71(7):924. PubMed ID: 25023554
    [No Abstract]   [Full Text] [Related]  

  • 12. [Diagnostic criteria and differential diagnosis of neuromyelitis optica].
    Nakashima I
    Nihon Rinsho; 2014 Nov; 72(11):1964-9. PubMed ID: 25518378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distinct brain imaging characteristics of autoantibody-mediated CNS conditions and multiple sclerosis.
    Jurynczyk M; Geraldes R; Probert F; Woodhall MR; Waters P; Tackley G; DeLuca G; Chandratre S; Leite MI; Vincent A; Palace J
    Brain; 2017 Mar; 140(3):617-627. PubMed ID: 28364548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders.
    Kezuka T; Tanaka K; Matsunaga Y; Goto H
    Neurology; 2014 Jul; 83(5):475. PubMed ID: 25074893
    [No Abstract]   [Full Text] [Related]  

  • 15. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders.
    Mao Z; Lu Z; Hu X
    Neurology; 2014 Sep; 83(12):1122. PubMed ID: 25224530
    [No Abstract]   [Full Text] [Related]  

  • 16. Author response.
    Sato DK; Takahashi T; Waters PJ; Fujihara K
    Neurology; 2014 Jul; 83(5):475-6. PubMed ID: 25215376
    [No Abstract]   [Full Text] [Related]  

  • 17. Author response.
    Sato DK; Callegaro D; Lana-Peixoto MA; Horizonte B; Nakashima I; Fujihara K
    Neurology; 2014 Sep; 83(12):1122-3. PubMed ID: 25356464
    [No Abstract]   [Full Text] [Related]  

  • 18. [Neuromyelitis optica: a clinical update].
    Chiquete E; Navarro-Bonnet J; Ayala-Armas R; Gutiérrez-Gutiérrez N; Solórzano-Meléndez A; Rodríguez-Tapia D; Gómez-Rincón M; Ruiz-Sandoval JL
    Rev Neurol; 2010 Sep; 51(5):289-94. PubMed ID: 20669128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MOG-IgG in neuromyelitis optica.
    Luppe S; Robertson NP
    J Neurol; 2014 Mar; 261(3):640-2. PubMed ID: 24532204
    [No Abstract]   [Full Text] [Related]  

  • 20. The clinical spectrum associated with myelin oligodendrocyte glycoprotein antibodies (anti-MOG-Ab) in Thai patients.
    Siritho S; Sato DK; Kaneko K; Fujihara K; Prayoonwiwat N
    Mult Scler; 2016 Jun; 22(7):964-8. PubMed ID: 26498263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.